Bosutinib dosage and usage

Bosutinib (Bosutinib) is an oral targeted drug used to treat chronic myelogenous leukemia (CML). The method of use and dosage need to be determined according to the patient's specific condition and the doctor's judgment. The following is a general dosage guide, but please note that this is only a general recommendation, and the specific dosage plan should be formulated by a professional doctor based on the patient's condition.

1. Initial dose (Induction Dose): The initial dose of bosutinib is usually determined based on the patient's weight and overall health. In general, the standard starting dose is 400 mg daily, which can be adjusted based on patient tolerance and treatment effectiveness. In some special cases, the doctor may adjust the initial dose, and the specific dose adjustment should follow the doctor's recommendation.

2. Daily Administration Time (Administration Time): Bosutinib is usually taken orally once a day, and it is recommended to take it at the same time to ensure stable blood concentration. Patients should choose a fixed daily medication time under the advice of their doctor and try to keep it as consistent as possible.

3. With or Without Food: Bosutinib can be administered before or after meals. Typically, patients are advised to take it after meals to reduce the occurrence of stomach upset. The oral medication can be taken with light snacks or biscuits, but it is not recommended to take it with high-fat foods as this may affect the absorption of the medication.

4. Dose Adjustment (Dose Adjustment): Dose adjustment may be an important part of the treatment process. Physicians will determine whether dose adjustment is necessary based on the patient's clinical response, adverse effects, and specific treatment goals. Patients should not adjust medication dosages on their own and should make any adjustments under the guidance of their physician.

5. Maintenance Therapy: ForCMLPatients with bosutinib usually require long-term maintenance therapy. The goal of continued treatment is to control the development of leukemia and maintain the patient's stable condition. Patients should follow the doctor's instructions for regular follow-up visits and receive relevant examinations to monitor the development of the disease and the efficacy of the drug.

6. Notes (Considerations): During the use of bosutinib, patients need to pay close attention to any symptoms of discomfort and report them to their doctor in a timely manner. Doctors may adjust treatment based on the patient's clinical condition and laboratory test results. In addition, patients should also undergo regular hematology tests, electrocardiogram monitoring, etc. to ensure the stability of various body indicators.

It needs to be emphasized that the dosage and usage mentioned above are only general recommendations, and specific treatment plans should be formulated by professional doctors based on the individual differences and condition of the patient. Patients should closely follow medical instructions and maintain close communication with their doctors while using bosutinib to ensure the best therapeutic effect.

Bosutinib is not yet available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.